30-Day Postoperative Complications After Surgical Treatment of Proximal Humerus Fractures: Reverse Total Shoulder Arthroplasty Versus Hemiarthroplasty.


Journal

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
ISSN: 2474-7661
Titre abrégé: J Am Acad Orthop Surg Glob Res Rev
Pays: United States
ID NLM: 101724868

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 20 06 2022
accepted: 22 12 2022
entrez: 3 3 2023
pubmed: 4 3 2023
medline: 8 3 2023
Statut: epublish

Résumé

The purpose of this study was to evaluate risk factors associated with complications after reverse total shoulder arthroplasty (TSA) and hemiarthroplasty for the treatment of proximal humerus fractures. A retrospective review of the American College of Surgeons National Surgical Quality Improvement Program database was conducted. Current Procedural Terminology codes were used to identify patients treated for proximal humerus fracture with reverse TSA or hemiarthroplasty between 2005 and 2018. One thousand five hundred sixty-three shoulder arthroplasties were conducted: 436 hemiarthroplasties and 1,127 reverse TSA. The overall complication rate was 15.4% (15.7% reverse TSA; 14.7% hemiarthroplasty) (P = 0.636). Most frequent complications included transfusion 11.1%, unplanned readmission 3.8%, and revision surgery 2.1%. A 1.1% incidence of thromboembolic events was noted. Complications occurred most frequently in patients older than 65 years; male; and patients with anemia, American Society of Anesthesiologists classification III-IV, inpatient procedure, bleeding disorders, duration of surgery >106 minutes, and length of stay >2.5 days. Patients with body mass index >36 kg/m2 had a decreased risk of 30-day postoperative complications. There was a 15.4% complication rate in the early postoperative period. In addition, no notable difference was found in complication rates between groups (hemiarthroplasty: 14.7%; reverse TSA 15.7%). Future studies are needed to determine whether there is a difference between these groups in the long-term outcome and survivorship of these implants.

Identifiants

pubmed: 36867524
doi: 10.5435/JAAOSGlobal-D-22-00174
pii: 01979360-202303000-00002
pmc: PMC9988290
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons.

Références

J Bone Joint Surg Am. 1970 Sep;52(6):1090-103
pubmed: 5455340
J Shoulder Elbow Surg. 2016 Apr;25(4):608-13
pubmed: 26475637
J Bone Joint Surg Am. 2013 Nov 20;95(22):2050-5
pubmed: 24257664
Orthop Traumatol Surg Res. 2016 Sep;102(5):569-73
pubmed: 27118097
J Shoulder Elbow Surg. 2015 Oct;24(10):1560-6
pubmed: 25958208
J Shoulder Elbow Surg. 2016 Feb;25(2):330-40
pubmed: 26644230
J Orthop Trauma. 2015 Jan;29(1):60-8
pubmed: 25186842
Epidemiology. 1996 Nov;7(6):612-8
pubmed: 8899387
Int Orthop. 2016 Sep;40(9):1919-25
pubmed: 27194158
Int Orthop. 2016 Mar;40(3):531-9
pubmed: 26105763
Orthopedics. 2017 Jul 1;40(4):e641-e647
pubmed: 28418573
J Orthop Trauma. 2016 Aug;30 Suppl 2:S9-S10
pubmed: 27441943
J Shoulder Elbow Surg. 2017 Sep;26(9):1539-1545
pubmed: 28412103
Orthopedics. 2016 May 1;39(3):e465-73
pubmed: 27045483
J Arthroplasty. 2018 Mar;33(3):865-871
pubmed: 29107493
J Shoulder Elbow Surg. 2016 Jul;25(7):1133-7
pubmed: 26897312
Open Orthop J. 2017 Sep 30;11:1108-1114
pubmed: 29152005
Indian J Orthop. 2016 Nov-Dec;50(6):590-594
pubmed: 27904212
J Am Acad Orthop Surg. 2017 Jan;25(1):42-52
pubmed: 28002214
J Bone Joint Surg Am. 2014 Feb 5;96(3):251-61
pubmed: 24500588
J Shoulder Elbow Surg. 2014 Feb;23(2):279-89
pubmed: 24418780
J Shoulder Elbow Surg. 2014 Oct;23(10):1419-26
pubmed: 25086490
J Shoulder Elbow Surg. 2016 Oct;25(10):1690-8
pubmed: 27090009

Auteurs

Michael Khazzam (M)

From the Department of Orthopaedic Surgery, Shoulder Service, University of Texas Southwestern Medical Center, Dallas, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH